{
    "organizations": [],
    "uuid": "292d7f0b8c2f04207128bdfa82ba5f28bcb256ed",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-inventiva-says-lanifibranor-carcin/brief-inventiva-says-lanifibranor-carcinogenicity-studies-are-progressing-as-planned-idUSFWN1RA0V1",
    "ord_in_thread": 0,
    "title": "BRIEF-Inventiva Says Lanifibranor Carcinogenicity Studies Are Progressing As Planned",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 28 (Reuters) - INVENTIVA SA:\n* LANIFIBRANOR CARCINOGENICITY STUDIES: PROGRESSING AS PLANNED\n* LANIFIBRANOR CARCINOGENICITY STUDIES: INTERIM RESULTS IN RATS INDICATE NO COMPOUND RELATED URINARY BLADDER TUMORS\n* 104-WEEK IN-LIFE PERIOD COMPLETED\n* FINAL PEER-REVIEWED RESULTS EXPECTED FOR BOTH SPECIES BY END OF Q2 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-29T00:21:00.000+03:00",
    "crawled": "2018-03-29T16:14:40.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "inventiva",
        "sa",
        "lanifibranor",
        "carcinogenicity",
        "study",
        "progressing",
        "planned",
        "lanifibranor",
        "carcinogenicity",
        "study",
        "interim",
        "result",
        "rat",
        "indicate",
        "compound",
        "related",
        "urinary",
        "bladder",
        "tumor",
        "period",
        "completed",
        "final",
        "result",
        "expected",
        "specie",
        "end",
        "q2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}